Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Pfizer Inc.
54 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
Consumer Healthcare
GSK and Pfizer’s Combined Consumer Healthcare Business Will Focus on the U.S. and China
PAO-M04-19-NI-016
Announcement
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
PR-M03-19-NI-062
Licensing
Pfizer Licenses AnTolRx Type 1 Diabetes Candidate
PAO-M03-19-NI-021
Oncology
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
PR-M03-19-NI-005
Licensing Agreement
Pfizer to License AbbVie’s Humira IP
PAO-M12-18-NI-006
Biosimilars
Pfizer’s Rituximab Biosimilar Achieves Positive Study Results
PAO-M12-18-NI-001
FDA Approval
US FDA Approves Third Pfizer Cancer Drug in Two Months
PAO-M11-18-NI-014
New Partnership
Neuroscience Company Created by Bain Capital and Pfizer
PAO-M11-18-NI-004
Breakthrough Therapy
Pfizer Granted FDA Breakthrough Therapy Designation for 20-valent Pneumococcal Conjugate Vaccine
PR-M10-18-NI-001
Collaboration
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
PR-M09-18-NI-052
Marketing Authorization
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
PR-M08-18-NI-024
European Approval
Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)
PR-M08-18-NI-014
New Facility
Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs
PR-M07-18-NI-092
Collaboration
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
PR-M07-18-NI-065
Pricing
Pfizer Announces it Will Defer Company’s Price Increases
PR-M07-18-NI-036
Investment
Pfizer Expands Investment in Biotech through Pfizer Ventures
PAO-M06-18-NI-010
Approval
U.S. FDA and European Medicines Agency Accept Regulatory Submissions for Review of Talazoparib for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
PR-M06-18-NI-036
FDA Approval
Pfizer Announces U.S. FDA Approves XELJANZ® (tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis
PR-M06-18-NI-012
Breakthrough Designation
Pfizer’s XALKORI® (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
PR-M05-18-NI-113
Study Results
A Study Analyzing Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+
PR-M05-18-NI-096
Clinical Study
Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
PR-M05-18-NI-092
Phase 3 Trial
LYRICA® (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
PR-M05-18-NI-077
FDA Approval
Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA
PR-M05-18-NI-071
Drug Discovery
XtalPi Inc. Announces Strategic Research Collaboration with Pfizer Inc. to Develop Artificial Intelligence-Powered Molecular Modeling Technology for Drug Discovery
PR-M05-18-NI-041
1
3
»
